The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models
暂无分享，去创建一个
R. Dienstmann | O. Díez | S. Gutiérrez‐Enríquez | J. Balmaña | A. Llop-Guevara | A. Staniszewska | Elisabetta Leo | H. Verdaguer | F. Pedretti | M. Guzman | A. Herencia-Ropero | E. J. Arenas | Joanna Domènech-Vivó | J. Forment | Sara Talbot | Joaquin Arribas | V. Serra | O. Rodríguez | Alan Lau | Paolo Nuciforo | Eduardo García-Galea | A. Moles‐Fernández | Teresa Macarulla | Mark J O'Connor | Heura Domènech | Fernando J Calero-Nieto | Luis Tobalina | Mark Albertella